01:38:30 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-02-15 Bokslutskommuniké 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-04-20 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-12 Kvartalsrapport 2022-Q1
2022-04-20 Årsstämma 2022
2022-04-07 Ordinarie utdelning TRVX 0.00 NOK
2022-02-17 Bokslutskommuniké 2021
2021-11-25 Extra Bolagsstämma 2021
2021-11-04 Kvartalsrapport 2021-Q3
2021-08-18 Kvartalsrapport 2021-Q2
2021-05-06 Kvartalsrapport 2021-Q1
2021-03-18 Ordinarie utdelning TRVX 0.00 NOK
2021-03-17 Årsstämma 2021
2021-02-18 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-07 Kvartalsrapport 2020-Q1
2020-04-30 Ordinarie utdelning TRVX 0.00 NOK
2020-04-29 Årsstämma 2020
2020-03-11 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-09 Kvartalsrapport 2019-Q1
2019-04-10 Ordinarie utdelning TRVX 0.00 NOK
2019-04-09 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-01 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-05-03 Kvartalsrapport 2018-Q1
2018-04-12 Ordinarie utdelning TRVX 0.00 NOK
2018-04-11 Årsstämma 2018
2018-02-15 Bokslutskommuniké 2017
2017-11-16 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-04-25 Kvartalsrapport 2017-Q1
2017-04-05 Årsstämma 2017
2017-02-16 Bokslutskommuniké 2016
2016-11-17 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-12 Kvartalsrapport 2016-Q1
2016-04-14 Ordinarie utdelning TRVX 0.00 NOK
2016-04-13 Årsstämma 2016
2015-06-23 Ordinarie utdelning TRVX 0.00 NOK
2015-06-22 Årsstämma 2015

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Targovax är ett läkemedelsbolag. Bolaget specialistkompetens återfinns inom riktad immunterapi som används vid behandling av cancerpatienter. Bolagets verksamhet består av forskning och utveckling och läkemedlen säljs idag under separata varumärken. Ett flertal partnerskap på marknaden har ingåtts för att stärka samarbetet inom utvecklingen av ny immunterapi. Bolaget grundades 2010 och har sitt huvudkontor i Oslo.
2022-11-03 07:00:00

Oslo, Norway, 3 November 2022 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its third quarter 2022 results.

Members of Targovax's executive management team will give an online presentation to investors, analysts and the press at 10:00 CET today (details below).

THIRD QUARTER 2022 HIGHLIGHTS

ONCOS-102
  • The study protocol for the planned multi-cohort phase 2 in melanoma was approved by the US FDA
  • The phase 1b melanoma study results were selected for oral presentation at the prestigious Society for Immunotherapy in Cancer (SITC) annual meeting
  • The phase 1b melanoma study results were published in the high-impact oncology journal "Clinical Cancer Research"
CircRNA pipeline program
  • Key technical proof-of-concept data were established for the circRNA program
Mutant KRAS platform
  • Preparations progressed for the TG01 mutant KRAS trials - one in Norway and one in the USA

Erik Digman Wiklund, CEO commented: "It is a very exciting time to lead Targovax.  We are building a great pipeline and have established a robust development strategy for our clinical stage products. During the third quarter we made important progress on all three of our strategic pillars, and Targovax is in a strong position to build success for both the clinical and pre-clinical parts of our portfolio."

Key figures

Amounts in NOK 3Q 2022 3Q 2021 9M 2022 9M 2021 FY 2021
thousands

Total operating - - - - -
revenues
Total operating -20 282 -22 539 -80 069 -70 078 -95 601
expenses
Operating -20 282 -22 539 -80 069 -70 078 -95 601
profit/loss
Net financial items -460 -781 -296 -1 294 -2 422
Income tax 10 11 31 42 52
Net profit/loss -20 732 -23 309 -80 333 -71 330 -97 971

Basic and diluted  -0.11  -0.27  -0.43  -0.82  -1.10
EPS (NOK/share)

Net change in cash -29 612 -17 127 -85 496 -68 257 59 360
Cash and cash 125 798 71 192 181 682 122 321 122 321
equivalents start of
period
Cash and cash 96 186 54 064 96 186 54 064 181 682
equivalents end of
period

  The interim financial information has not been subject to audit

Presentation

We invite to a live webcast today at 10.00 CET. You can join the webcast here (https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20221103_8). It will be possible to submit questions during the presentation.

Reporting material

221103 TRVX 3Q report.pdf (https://mb.cision.com/Public/17093/3660342/b691e5b95c6dfe8c.pdf)

221103 TRVX 3Q presentation.pdf (https://mb.cision.com/Public/17093/3660342/9767c15424e1c764.pdf)

The quarterly report and presentation are also available at the website  www.targovax.com (https://www.targovax.com/en/financial-reports/).